Dr. Batlevi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1275 York Ave
Box # 330
New York, NY 10065Phone+1 646-608-3707
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2016
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2010 - 2012
University of Massachusetts Medical SchoolClass of 2010
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2018 - 2025
NY State Medical License 2011 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL Start of enrollment: 2013 Jun 13
- A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma Start of enrollment: 2016 May 09
- A Study to Assess the Long-term Safety of Tazemetostat Start of enrollment: 2016 Aug 30
- Join now to see all
Publications & Presentations
PubMed
- 49 citationsZanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or ...Jacob D. Soumerai, Anthony R. Mato, Ahmet Dogan, Venkatraman E. Seshan, Erel Joffe
The Lancet. Haematology. 2021-12-01 - 28 citationsThe International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell TherapyMarta Garcia-Recio, Kitsada Wudhikarn, Martina Pennisi, Rosalia Alonso-Trillo, Jessica Flynn
Transplantation and Cellular Therapy. 2021-03-01 - 27 citationsOutcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma.Ana Alarcon Tomas, Joshua A Fein, Shalev Fried, Jessica R Flynn, Sean M Devlin
Leukemia. 2023-01-01
Abstracts/Posters
- Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor EvolutionConnie Lee Batlevi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T CellsConnie Lee Batlevi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin LymphomaConnie Lee Batlevi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL “Armored” CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Tr...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
Combination of Ibrutinib and Buparlisib Shows Promise in MCL and Other NHLsJune 16th, 2017
Grant Support
- Notch Survivin Signaling In Breast CancerNational Cancer Institute2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
